US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

TNGX Tango Therapeutics Inc

2.79

0.00 (0.00%)

Pre Mercado

Última actualización: 03:32:37

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

10/21/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/Aaron I. Davis, Managing Member

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Tango Therapeutics (NASDAQ:TNGX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Haga Click aquí para más Gráficas Tango Therapeutics.

Tango Therapeutics (NASDAQ:TNGX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024

Haga Click aquí para más Gráficas Tango Therapeutics.

Noticias sobre Tango Therapeutics Inc TNGX

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Martes 3 de Diciembre 2024 (2 semanas hace) • Business Wire

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Miércoles 27 de Noviembre 2024 (3 semanas hace) • Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Miércoles 20 de Noviembre 2024 (4 semanas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 18 de Noviembre 2024 (1 mes hace) • Edgar (US Regulatory)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Jueves 7 de Noviembre 2024 (1 mes hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Miércoles 6 de Noviembre 2024 (1 mes hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Miércoles 6 de Noviembre 2024 (1 mes hace) • Edgar (US Regulatory)

Form 8-K - Current report
Miércoles 6 de Noviembre 2024 (1 mes hace) • Edgar (US Regulatory)

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Miércoles 6 de Noviembre 2024 (1 mes hace) • Business Wire

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
Miércoles 6 de Noviembre 2024 (1 mes hace) • Business Wire

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Lunes 28 de Octubre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Viernes 25 de Octubre 2024 (2 meses hace) • Edgar (US Regulatory)

Más de Tango Therapeutics Inc Artículos de Noticias

US Dollar vs MXN

JP Morgan Chase

Deutsche Telekom (QX)

BNP Paribas (QX)

Gold vs US Dollar

Verizon Communications

Financial Select Sector

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones